Showing results (441-450 of 864) with videos related to
Sort By:
Pageof 87
Current Drug Discovery Technologies|February 16, 2019
Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example with LamivudineKushal Shah, Briann Fischetti, Agnes Cha, et al.Current Drug Discovery Technologies|May 23, 2006
Fine-grained statistical torsion angle potentials are effective in discriminating native protein structuresAlessandro Albiero, Silvio C E TosattoCurrent Drug Discovery Technologies|May 23, 2006
Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathySho-ichi Yamagishi, Kazuo Nakamura, Takanori MatsuiCurrent Drug Discovery Technologies|August 24, 2006
Novel anti-bacterials against MRSA: synthesis of focussed combinatorial libraries of tri-substituted 2(5H)-furanonesEric Lattmann, Nison Sattayasai, Carl S Schwalbe, et al.Current Drug Discovery Technologies|August 24, 2006
Protein conformational diseases: from mechanisms to drug designsJin-Chung Lin, Hsuan-Liang LiuCurrent Drug Discovery Technologies|November 30, 2007
Recognition of lysine residues on protein surfaces using calixarenes and its applicationTatsuya Oshima, Yoshinari Baba, Kojiro Shimojo, et al.Current Drug Discovery Technologies|November 30, 2007
Thermal properties and microstructures of methylated polyrotaxane solutionsToshiyuki Kataoka, Masatoshi Kidowaki, Changming Zhao, et al.Current Drug Discovery Technologies|February 14, 2006
Genetically engineered mouse models for drug discovery: new chemical genetic approachesSusanne Heck, Xiaobing Qian, Mark VellecaCurrent Drug Discovery Technologies|February 14, 2006
The FlexX database docking environment--rational extraction of receptor based pharmacophoresHolger Claussen, Marcus Gastreich, Volker Apelt, et al.Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial dataEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.Pageof 87